SELDI-TOF mass spectrometry evaluation of variant transthyretins for diagnosis and pathogenesis of familial amyloidotic polyneuropathy

Clinical Chemistry

Volumn 55, Issue 6, 2009, Pages 1223-1227

  Ueda, Mitsuharu ^a   Misumi, Yohei ^a   Mizuguchi, Mineyuki ^b   Nakamura, Masaaki ^c   Yamashita, Taro ^a   Sekijima, Yoshiki ^d   Ota, Kazutoshi ^a   Shinriki, Satoru ^a   Jono, Hirofumi ^a   Ikeda, Shu Ichi ^d   Suhr, Ole B ^e   Ando, Yukio ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c NATIONAL INSTITUTE FOR MINAMATA DISEASE   (Japan)

^d SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; CYSTEINE; PREALBUMIN; TYROSINE;

ARTICLE; CONTROLLED STUDY; EVALUATION; FAMILIAL AMYLOID POLYNEUROPATHY; GENE MUTATION; HUMAN; HUMAN TISSUE; PATHOGENESIS; PROTEIN VARIANT; QUANTITATIVE ASSAY; RELIABILITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

AMYLOID NEUROPATHIES, FAMILIAL; HUMANS; PREALBUMIN; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 66449135352     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2008.118505     Document Type: Article

References (18)

1. Ando Y, Nakamura M, Araki S. Transthyretinrelated familial amyloidotic polyneuropathy. Arch Neurol 2005;62:1057-1062
2. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007;36:411-423 (Pubitemid 47512065)
3. Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003;10:160-185 (Pubitemid 37372400)
4. Holmgren G, Ericzon BG, Groth CG, Steen L, Suhr O, Andersen O, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993;341:1113-1116 (Pubitemid 23125854)
5. Suhr OB, Herlenius G, Friman S, Ericzon BG. Liver transplantation for hereditary transthyretin amyloidosis. Liver Transpl 2000;6:263-276 (Pubitemid 30317220)
6. Ando Y, Ohlsson PI, Suhr O, Nyhlin N, Yamashita T, Holmgren G, et al. A new simple and rapid screening method for variant transthyretin-related amyloidosis. Biochem Biophys Res Commun 1996;228:480-483 (Pubitemid 26396098)
7. Shimizu A, Nakanishi T, Miyazaki A. Detection and characterization of variant and modified structures of proteins in blood and tissues by mass spectrometry. Mass Spectrom Rev 2006;25: 686-712. (Pubitemid 44330227)
8. Mitsuhashi S, Yazaki M, Tokuda T, Sekijima Y, Washimi Y, Shimizu Y, et al. Biochemical characteristics of variant transthyretins causing hereditary leptomeningeal amyloidosis. Amyloid 2005; 12:216-225 (Pubitemid 43096380)
9. Kiehntopf M, Siegmund R, Deufel T. Use of SELDITOF mass spectrometry for identification of new biomarkers: potential and limitations. Clin Chem Lab Med 2007;45:1435-1449 (Pubitemid 350036581)
10. Ching J, Voivodov KI, Hutchens TW. Surface chemistries enabling photoinduced uncoupling/ desorption of covalently tethered biomolecules. J Org Chem 1996;61:3582-3583 (Pubitemid 126532644)
11. Kaplan B, Hrncic R, Murphy CL, Gallo G, Weiss DT, Solomon A. Microextraction and purification techniques applicable to chemical characterization of amyloid proteins in minute amounts of tissue. Methods Enzymol 1999;309:67-81. (Pubitemid 29446442)
12. Matsubara K, Mizuguchi M, Igarashi K, Shinohara Y, Takeuchi M, Matsuura A, et al. Dimeric transthyretin variant assembles into spherical neurotoxins. Biochemistry 2005;44:3280-3288 (Pubitemid 40326263)
13. Schweigert FJ, Wirth K, Raila J. Characterization of the microheterogeneity of transthyretin in plasma and urine using SELDI-TOF-MS immunoassay. Proteome Sci 2004;2:5. (Pubitemid 41630801)
14. Ando Y, Yamashita T, Nakamura M, Tanaka Y, Hashimoto M, Tashima K, et al. Down regulation of a harmful variant protein by replacement of its normal protein. Biochim Biophys Acta 1997;1362: 39-46. (Pubitemid 28027110)
15. Hammarström P, Sekijima Y, White JT, Wiseman RL, Lim A, Costello CE, et al. D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? Biochemistry 2003;42:6656-6663
16. Nakamura M, Yamashita T, Ueda M, Obayashi K, Sato T, Ikeda T, et al. Neuroradiologic and clinicopathologic features of oculoleptomeningeal type amyloidosis. Neurology 2005;65:1051-1056 (Pubitemid 41429630)
17. Sekijima Y, Hammarström P, Matsumura M, Shimizu Y, Iwata M, Tokuda T, et al. Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology. Lab Invest 2003;83:409-417 (Pubitemid 36351002)
18. Sekijima Y, Wiseman RL, Matteson J, Hammarström P, Miller SR, Sawkar AR, et al. The biological and chemical basis for tissue-selective amyloid disease. Cell 2005;121:73-78 (Pubitemid 40501169)